Planned Parenthood plans to withdraw from Title X program, amid looming Trump Administration rule changes; a new cure accepted by the FDA for a deadly strain of tuberculosis has been found to have a 90% success rate in a patient trial; opioid distribution to patients has began to change amongst doctors with new recommendations based around set prescribing levels.
Planned Parenthood announced Wednesday it will soon leave Title X, the federal family planning program, barring a court decision to delay Trump administration rules that bar clinics from referring patients for abortions, Associated Press reported. HHS stated the agency's willingness to accommodate clinics that are making efforts to comply with upcoming rule changes, but Planned Parenthood's spokeswoman Erica Sackin stated the organization’s intent to leave the program, due to regulations set to take effect September 18.A small trial consisting of 109 patients has shown a groundbreaking success rate of 90% against a deadly strain of drug-resistant tuberculosis. This particular XDR strain is involved in about 30,000 cases in over 100 countries, with a cure rate of only 34%. The New York Times reported that the FDA has endorsed the new approach by approving the use of 3 pills: pretomanid, bedaquiline, and linezolid. The treatment can soon come into use worldwide. Narcotic prescriptions have been reduced by nearly one-third since October 2017, after growing concern about the opioid crisis, Kaiser Health News reports. Surgeons stated the transition of narcotic prescriptions have changed dramatically since the beginning of their careers as there was little or no information recommended to them about pill distribution to patients after procedures. The Michigan OPEN guidelines now recommends for no more than 10 pills, equivalent to 5 mg of oxycodone, for an operation such as a minor hernia repair, as opposed to the 29 pills prescribed in the past.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More